Professional Media briefs

Share this article:
Archives of Neurology said that its incremental online-first publishing, which the journal started in January, will increase to four articles online per week this month and then will go up to five each week in March, for a total of 20 articles published online ­immediately after acceptance each month. The journal said the initiative is part of an effort to expedite the peer-review process.

The journal Science fully retracted a controversial study that had linked a mouse leukemia retrovirus to chronic fatigue syndrome. The withdrawal follows a statement in September by the Cleveland Clinic, which said some of the study's findings had resulted from lab contamination, and other concerns about the research.

Springer's Journal of Pharmacokinetics and Pharmacodynamics announced an affiliation with the American Society of Pharmacometrics, starting this year. Publishing six issues per year, the journal presents research for pharmaceutical scientists working in both industry and academia.

Elsevier said it acquired The Ocular Surface, a quarterly peer-reviewed journal focusing on the external eye and vision. The journal has been published by Ethis Communications.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?